Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1434-9949

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis ; volume:38 ; number:12 ; day:8 ; month:8 ; year:2019 ; pages:3381-3390 ; date:12.2019
Clinical rheumatology ; 38, Heft 12 (8.8.2019), 3381-3390, 12.2019

Creator: Edwards, Christopher J.
Monnet, Joëlle
Ullmann, Martin
Vlachos, Pantelis
Chyrok, Veranika
Ghori, Vishal

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10067-019-04679-y

URN: urn:nbn:de:101:1-2020051022202678777882

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Edwards, Christopher J.
Monnet, Joëlle
Ullmann, Martin
Vlachos, Pantelis
Chyrok, Veranika
Ghori, Vishal
SpringerLink (Online service)

Other Objects (12)

AVT02: An Adalimumab Biosimilar

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Correction to: AVT02: An Adalimumab Biosimilar

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Correction to: AVT02: An Adalimumab Biosimilar

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Correction to: AVT02: An Adalimumab Biosimilar

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

AVT02: An Adalimumab Biosimilar

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Correction to: AVT02: An Adalimumab Biosimilar

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Correction to: AVT02: An Adalimumab Biosimilar

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Correction to: AVT02: An Adalimumab Biosimilar

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Related objects

Reset password